P. JOAN CHESNEY, M.D.; BARBARA A. CRASS, B.Sc.; MARCIA B. POLYAK, M.S.; PHILIP J. WAND, B.Sc.; THOMAS F. WARNER, M.B., B.Ch.; JAMES M. VERGERONT, M.D.; JEFFREY P. DAVIS, M.D.; ROBERT W. TOFTE, M.D.; RUSSELL W. CHESNEY, M.D.; MERLIN S. BERGDOLL, Ph.D.
Little information is available on the optimal management of toxic shock syndrome and on its sequelae. The most appropriate antibiotic treatment, the efficacy of colloid infusions, and the potential role of gamma globulin preparations have not yet been completely ascertained. Coagulase-positive staphylococci associated with toxic shock syndrome had minimal inhibitory concentrations of 0.06 µg/mL or less to rifampin, 0.25 µg/mL or less to gentamicin, and 0.50 µg/mL or less to both nafcillin and clindamycin. In the 36 patients studied abnormal chest roentgenograms were commoner in those who had received albumin than in those who had not. Radioimmunoassay showed antibody titers to staphylococcal enterotoxin F, a marker protein in toxic shock syndrome, of 1:4000 or more for intravenous gamma globulin (12/15 lots) and 1:40 000 or more for intramuscular gamma globulin. Major sequelae of toxic shock syndrome include late-onset rash, compromised renal function, cyanotic extremities, and prolonged neuromuscular abnormalities.
CHESNEY PJ, CRASS BA, POLYAK MB, WAND PJ, WARNER TF, VERGERONT JM, et al. Toxic Shock Syndrome: Management and Long-Term Sequelae. Ann Intern Med. ;96:847–851. doi: 10.7326/0003-4819-96-6-847
Download citation file:
Published: Ann Intern Med. 1982;96(6_Part_2):847-851.
Multi-Organ Failure and Sepsis, Pulmonary/Critical Care.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use